TY - JOUR
T1 - Analysis of pol integrase sequences in diverse HIV type 1 strains using a prototype genotyping assay
AU - Eshleman, Susan H.
AU - Hudelson, Sarah E.
AU - Smith, Peter
AU - Hackett, John
AU - Holzmayer, Vera
AU - Swanson, Priscilla
AU - Devare, Sushil G.
AU - Marlowe, Natalia
PY - 2009/3/1
Y1 - 2009/3/1
N2 - A prototype assay was used to genotype integrase (IN) from 120 HIV-1- infected IN inhibitor-naive adults from Argentina, Brazil, Cameroon, South Africa, Thailand, and Uganda. Subtype designations based on analysis of pol IN sequences were A (14), B (15), C (12), D (11), F (12), G (7), H (1), CRF01-AE (9), CRF02-AG (34), CRF22-01 A1 (4), and CRF37-cpx (1). Ten (8.3%) of 120 samples had mutations associated with reduced susceptibility to the IN inhibitors, raltegravir and elvitegravir. Two samples had E92Q (both subtype B) and eight had E157Q (2A, 1C, 1D, 1F, 3 CRF02-AG). Some samples had other mutations selected by these drugs including T97A, and some had amino acid polymorphisms at positions associated with raltegravir and elvitegravir resistance. Mutations associated with other investigational HIV IN inhibitors were also identified. This suggests that HIV strains may vary in their natural susceptibility to HIV IN inhibitors.
AB - A prototype assay was used to genotype integrase (IN) from 120 HIV-1- infected IN inhibitor-naive adults from Argentina, Brazil, Cameroon, South Africa, Thailand, and Uganda. Subtype designations based on analysis of pol IN sequences were A (14), B (15), C (12), D (11), F (12), G (7), H (1), CRF01-AE (9), CRF02-AG (34), CRF22-01 A1 (4), and CRF37-cpx (1). Ten (8.3%) of 120 samples had mutations associated with reduced susceptibility to the IN inhibitors, raltegravir and elvitegravir. Two samples had E92Q (both subtype B) and eight had E157Q (2A, 1C, 1D, 1F, 3 CRF02-AG). Some samples had other mutations selected by these drugs including T97A, and some had amino acid polymorphisms at positions associated with raltegravir and elvitegravir resistance. Mutations associated with other investigational HIV IN inhibitors were also identified. This suggests that HIV strains may vary in their natural susceptibility to HIV IN inhibitors.
UR - http://www.scopus.com/inward/record.url?scp=65449116538&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=65449116538&partnerID=8YFLogxK
U2 - 10.1089/aid.2008.0236
DO - 10.1089/aid.2008.0236
M3 - Article
C2 - 19327053
AN - SCOPUS:65449116538
SN - 0889-2229
VL - 25
SP - 343
EP - 345
JO - AIDS Research and Human Retroviruses
JF - AIDS Research and Human Retroviruses
IS - 3
ER -